Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients
Key result
Transendocardial administration of allo-MSCs appears safe and feasible in patients with anthracycline-induced cardiomyopathy, with 97% of subjects undergoing successful injections.
Why the study?
Anthracycline-induced cardiomyopathy may be irreversible with poor prognosis, and administration of allogeneic bone marrow-derived mesenchymal stromal cells represents a promising heart failure treatment approach.
Does transendocardial administration of allogeneic mesenchymal stromal cells improve safety, feasibility, and clinical outcomes in patients with anthracycline-induced cardiomyopathy heart failure?
Population
Patients with anthracycline-induced cardiomyopathy
Comparison
Transendocardial allo-MSCs vs vehicle
Design
Phase 1 study
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Supports progression to efficacy trials of allo-MSCs in anthracycline cardiomyopathy; extends cell therapy safety data to this population.
Study Design
Type
RCT
Structured PICO
Does transendocardial administration of allogeneic mesenchymal stromal cells improve safety, feasibility, and clinical outcomes in patients with anthracycline-induced cardiomyopathy heart failure?
P
Population
Patients with anthracycline-induced cardiomyopathy heart failure followed for 1 year.
I
Intervention
Allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) administered transendocardially.
C
Comparator
Vehicle administered transendocardially.
O
Outcome
Safety and feasibility.safety
Transendocardial administration of allogeneic mesenchymal stromal cells is safe and feasible in patients with anthracycline-induced cardiomyopathy, laying the groundwork for phase 2 efficacy trials.
Cite This Study
Bolli et al. (2020) conducted an RCT in Anthracycline-induced cardiomyopathy (AIC) heart failure. Allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) vs. Vehicle was evaluated on Safety and feasibility. Transendocardial administration of allo-MSCs appears safe and feasible in patients with anthracycline-induced cardiomyopathy, with 97% of subjects undergoing successful injections.